Damora Therapeutics (DMRA) Cash from Financing Activities (2020 - 2026)

Damora Therapeutics' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $295.9 million for Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $295.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $298.8 million (changed N/A YoY) and the FY2025 annual result came in at $266.8 million, changed N/A from the prior year.
• Cash from Financing Activities was $295.9 million for Q1 2026 at Damora Therapeutics, up from $171000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $295.9 million in Q1 2026 and bottomed at $23000.0 in Q1 2023.
• A 3-year average of $49.9 million and a median of $297500.0 in 2022 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 59.67% in 2023, while the deepest fall reached 59.67% in 2023.
• Damora Therapeutics' Cash from Financing Activities stood at $65000.0 in 2022, then soared by 163.08% to $171000.0 in 2023, then surged by 172953.22% to $295.9 million in 2026.
• Business Quant data shows DMRA's Cash from Financing Activities at $295.9 million in Q1 2026, $171000.0 in Q3 2023, and $2.7 million in Q2 2023.